Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ricky W Johnstone

Showing results (51-60 of 188) with videos related to

Pageof 19
Sort By:
Clinical Epigenetics|January 29, 2015
Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemiaJessica M Salmon, Michael Bots, Eva Vidacs, et al.
Annals of Hematology|October 16, 2010
MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi)Kate L Burbury, Mark J Bishton, Ricky W Johnstone, et al.
Molecular Cancer Therapeutics|May 17, 2008
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsinAndrea Newbold, Ralph K Lindemann, Leonie A Cluse, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2008
Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune responseJohn Stagg, Janelle Sharkey, Sandra Pommey, et al.
Biochemical and Biophysical Research Communications|December 8, 2004
Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2Kim S Cresswell, Christopher J P Clarke, Jacob T Jackson, et al.
Molecular and Cellular Biology|August 29, 2003
Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motifGrant A Darnell, Toni M Antalis, Ricky W Johnstone, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2011
Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodiesAilsa J Christiansen, Alison West, Kellie-Marie Banks, et al.
Blood|April 12, 2014
Id2 represses E2A-mediated activation of IL-10 expression in T cellsFrederick Masson, Margherita Ghisi, Joanna R Groom, et al.
Cancer Research|October 26, 2013
An intact immune system is required for the anticancer activities of histone deacetylase inhibitorsAlison C West, Stephen R Mattarollo, Jake Shortt, et al.
Histochemistry and Cell Biology|January 28, 2003
Expression of IFI 16 in epithelial cells and lymphoid tissuesWu Wei, Christopher J P Clarke, Gino R Somers, et al.
Pageof 19

Showing results (51-60 of 188) with videos related to

Sort By:
Pageof 19
Clinical Epigenetics|January 29, 2015
Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemiaJessica M Salmon, Michael Bots, Eva Vidacs, et al.
Annals of Hematology|October 16, 2010
MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi)Kate L Burbury, Mark J Bishton, Ricky W Johnstone, et al.
Molecular Cancer Therapeutics|May 17, 2008
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsinAndrea Newbold, Ralph K Lindemann, Leonie A Cluse, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2008
Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune responseJohn Stagg, Janelle Sharkey, Sandra Pommey, et al.
Biochemical and Biophysical Research Communications|December 8, 2004
Biochemical and growth regulatory activities of the HIN-200 family member and putative tumor suppressor protein, AIM2Kim S Cresswell, Christopher J P Clarke, Jacob T Jackson, et al.
Molecular and Cellular Biology|August 29, 2003
Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motifGrant A Darnell, Toni M Antalis, Ricky W Johnstone, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2011
Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodiesAilsa J Christiansen, Alison West, Kellie-Marie Banks, et al.
Blood|April 12, 2014
Id2 represses E2A-mediated activation of IL-10 expression in T cellsFrederick Masson, Margherita Ghisi, Joanna R Groom, et al.
Cancer Research|October 26, 2013
An intact immune system is required for the anticancer activities of histone deacetylase inhibitorsAlison C West, Stephen R Mattarollo, Jake Shortt, et al.
Histochemistry and Cell Biology|January 28, 2003
Expression of IFI 16 in epithelial cells and lymphoid tissuesWu Wei, Christopher J P Clarke, Gino R Somers, et al.
Pageof 19